Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

1,988JPY
1 Aug 2013
Price Change (% chg)

¥43 (+2.21%)
Prev Close
¥2,085
Open
¥1,938
Day's High
¥1,997
Day's Low
¥1,938
Volume
1,092,100
Avg. Vol
1,431,955
52-wk High
¥2,550
52-wk Low
¥1,497

4519.T

Chart for 4519.T

About

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company operates in two business segments. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transporta... (more)

Overall

Beta: 0.68
Market Cap (Mil.): ¥1,088,589.00
Shares Outstanding (Mil.): 559.69
Dividend: 23.00
Yield (%): 2.16

Financials

  4519.T Industry Sector
P/E (TTM): 20.35 37.93 37.76
EPS (TTM): 95.57 -- --
ROI: 10.14 19.48 18.76
ROE: 10.25 20.17 19.59
Search Stocks

REFILE-TABLE-Chugai Pharm -6-MTH group results (IFRS)

(Adds company forecast) Jul 25 - Chugai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 6 months ended 6 months ended Year to Jun 30, 2013 Jun 30, 2012 Dec 31, 2013 LATEST YEAR-AGO COMPANY RESULTS RESULT FORECAST Sales 201.02 185

25 Jul 2013

Sony to name Chugai Pharma's CEO as chairman-Nikkei

May 18 - Sony Corp plans to appoint Chugai Pharmaceutical Co Chief Executive Osamu Nagayama as chairman, the Nikkei reported.

17 May 2013

Roche says no plans to change holding in Japan's Chugai

LONDON, April 11 - Swiss drugmaker Roche has no plans to change its holding in Japan's Chugai Pharmaceutical and the recent weakening of the yen would not be a reason to trigger such a move.

11 Apr 2013

Roche says Japan approves new formulation of arthritis drug

ZURICH - Roche Holding AG's Japanese subsidiary Chugai said on Monday that Japanese health regulators have approved a new formulation of its rheumatoid arthritis drug Actemra.

25 Mar 2013

Roche says Japan approves new formulation of arthritis drug

ZURICH, March 25 - Roche Holding AG's Japanese subsidiary Chugai said on Monday that Japanese health regulators have approved a new formulation of its rheumatoid arthritis drug Actemra.

25 Mar 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$472.00
Provider: Datamonitor
$175.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks